Accès ouvert
2024
article
OpenAlex
Donna Rowen, Jill Carlton, Jan Henrik Terheyden, Robert Patrick Finger et autres
OBJECTIVES: This study generates VILL-UI (Vision Impairment in Low Luminance - Utility Index), a preference-weighted measure (PWM) derived from the VILL-33 measure for use in patients with age-related macular degeneration (AMD) and valued to generate United Kingdom and German preference weights. METHODS: …
de, gb
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Leon von der Emde, Merten Mallwitz, Marc Vaisband, Jan Hasenauer et autres
This study aimed to determine the retest variability of quantitative fundus autofluorescence (QAF) in patients with and without age-related macular degeneration (AMD) and evaluate the predictive value of patient reliability indices on retest reliability. A total of 132 eyes from 68 patients …
de, at, fr, it, pt, dk, gb, nl, ch, us
(code pays fourni par la source)
Accès ouvert
2023
erratum
OpenAlex
Davide Garzone, Jan Henrik Terheyden, Olivier Morelle, Maximilian W. M. Wintergerst et autres
The original version of this Article contained an error in the Methods section, under the subheading ‘Statistical analyses’, where the following sentence has been deleted:
de, us, fr, pt, dk, gb, nl, ch, it
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Davide Garzone, Jan Henrik Terheyden, Olivier Morelle, Maximilian W. M. Wintergerst et autres
Drusen are hallmarks of early and intermediate age-related macular degeneration (AMD) but their quantification remains a challenge. We compared automated drusen volume measurements between different OCT devices. We included 380 eyes from 200 individuals with bilateral intermediate (iAMD, n = 126), early …
de, us, fr, pt, dk, gb, nl, ch, it
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Jan Henrik Terheyden, Frank Gerhard Holz, Steffen Schmitz-Valckenberg, Anna Lüning et autres
BACKGROUND: There is an unmet need for treatment options in intermediate age-related macular degeneration (iAMD). However, for any new interventions to be tested in clinical trials, novel currently unavailable clinical endpoints need to be developed. Thus, the MACUSTAR study aims to develop …
de, gb, nl, ch, us, pt
(code pays fourni par la source)